Financial expense for the third quarter of 2012 decreased to nil from $0.27 million for the same period in 2011, mainly as a result of changes in valuation of the warrant liability.
For the quarter ended September 30, 2012, the Company reported a net loss of $3.03 million or $0.25 per share, compared with a net loss of $3.42 million or $0.35 per share in the comparable 2011 period.
Nine Month Financial Results
Gross R&D expense for the nine months ended September 30, 2012 was $5.13 million, up from $4.50 million for the same period in 2011 due to an increase in the use of materials and sub-contractors in connection with preparations for the Company’s ongoing Phase II EPODURE clinical trial in Israel and planned Phase II clinical trial in the U.S., preparations for the trials of INFRADURE in Israel and an increase in R&D personnel. For the nine months ended September 30, 2012, net R&D expense decreased to $3.36 million from $3.57 million for the comparable prior-year period due to the participation by the Israeli Office of the Chief Scientist of $1.77 million in the 2012 period compared with $0.86 million for the 2011 period, which was partially offset by higher gross R&D expenses as detailed above. General and administrative expense for the first nine months of 2012 was $5.60 million compared with $3.71 million for the first nine months of 2011 primarily due to increased fees for legal and professional services and stock-based compensation granted to consultants and directors. The Company’s net loss for the first nine months of 2012 was $12.69 million or $1.20 per share, compared with a net loss of $6.09 million or $0.76 per share for the same period of 2011.Balance Sheet Highlights As of September 30, 2012, Medgenics had cash and cash equivalents of $9.00 million, compared with $5.00 million as of December 31, 2011. For the nine months ended September 30, 2012, the Company used $5.87 million in net cash to fund operating activities, compared with $5.46 million for the nine months ended September 30, 2011.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV